GlassScriptPhysician profile
Michelle G Baechtold
NPI 1669867669
$9,156.57
in general payments reported to CMS, 2019-2025
29 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $443 · 2021: $1,239 · 2022: $1,978 · 2023: $1,643 · 2024: $1,493 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,783 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,782.64 |
| Education | $276.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,077.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $876.53 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $758.74 | 2020-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $722.29 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $601.21 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $553.17 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $395.00 | 2020-2025 | |
| Leo Pharma INC. | $388.06 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $384.51 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $376.17 | 2022-2025 | Sotyktu |
| Incyte Corporation | $356.85 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $337.00 | 2022 | |
| Amgen INC. | $318.80 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $222.09 | 2024-2025 | Nemluvio, Aklief |
| Strata Skin Sciences, INC. | $182.66 | 2023 | Xtrac |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $113.22 | 2019-2025 | Klisyri |
| Pfizer INC. | $97.10 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.80 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.96 | 2022-2023 | Spevigo |
| Mayne Pharma Commercial LLC | $34.74 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $33.61 | 2021 | |
| Arcutis Biotherapeutics, INC. | $31.63 | 2023 | |
| Celgene Corporation | $23.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.46 | 2021 | |
| Dermira, INC. | $17.67 | 2019 | |
| Biofrontera INC. | $17.64 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Vyne Pharmaceuticals INC. | $15.98 | 2020 | |
| Kyowa Kirin, INC. | $15.54 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Baechtold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.